Stockreport

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Rafael Holdings, Inc. Class B  (RFL) 
NASDAQ:AMEX Investor Relations: morningstar.com/funds/xnas/rytnx/quote.html
PDF First data on treatment of NPC1 with Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 [Read more]